Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease - Authors' reply

Lancet Gastroenterol Hepatol. 2023 Jul;8(7):604. doi: 10.1016/S2468-1253(23)00155-3.

Authors

Mads Israelsen¹, Nikolaj Torp², Stine Johansen², Maja Thiele², Aleksander Krag²; GALAXY and MicrobLiver consortia

Affiliations

¹ Department of Gastroenterology and Hepatology, Odense University Hospital, 5000 Odense, Denmark. Electronic address: mads.egerod.israelsen@rsyd.dk.
² Department of Gastroenterology and Hepatology, Odense University Hospital, 5000 Odense, Denmark; Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, 5000 Odense, Denmark.

PMID: 37301207
DOI: 10.1016/S2468-1253(23)00155-3

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Liver Cirrhosis*
Liver Diseases*
Rifaximin / therapeutic use

Substances

Rifaximin